Search

Your search keyword '"Day, John"' showing total 4,900 results

Search Constraints

Start Over You searched for: Author "Day, John" Remove constraint Author: "Day, John"
4,900 results on '"Day, John"'

Search Results

51. Recursive InterNetwork Architecture, Investigating RINA as an Alternative to TCP/IP (IRATI)

52. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial

54. Beyond Contractures in Spinal Muscular Atrophy: Identifying Lower-Limb Joint Hypermobility

58. Telomere shortening is a hallmark of genetic cardiomyopathies

60. Storied experiences of physical activity involvement, family membership and happiness

61. Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes

63. Conformational fingerprinting with Raman spectroscopy reveals protein structure as a translational biomarker of muscle pathology.

65. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial

67. Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry

68. Rasch Analysis of the Pediatric Quality of Life Inventory 4.0 Generic Core Scales Administered to Patients With Duchenne Muscular Dystrophy

69. Assessing the Assisted Six-Minute Cycling Test as a Measure of Endurance in Non-Ambulatory Patients with Spinal Muscular Atrophy (SMA)

71. Sunfish parts 1 and 2: 4-year efficacy and safety data of risdiplam in types 2 and 3 spinal muscular atrophy (SMA)

74. Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen

75. Miyoshi myopathy and limb girdle muscular dystrophy R2 are the same disease

76. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial

83. Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study

96. Venous Vascular Closure System Versus Manual Compression Following Multiple Access Electrophysiology Procedures: The AMBULATE Trial

98. Restoration of Tidal Marshes

99. Cerebrospinal Fluid Proteomic Changes after Nusinersen in Patients with Spinal Muscular Atrophy

Catalog

Books, media, physical & digital resources